Physician profile

Marquetta Williamson

Psychiatric/Mental Health (Nurse Practitioner) · Omaha, NE

NPI 1487127742

$927.70

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$600.50

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alkermes, INC. $294.92 2021-2024 Lybalvi
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $242.09 2021-2024 Caplyta
Teva Pharmaceuticals USA, INC. $124.94 2023 Uzedy
Vanda Pharmaceuticals INC. $121.47 2024 Fanapt
Idorsia Pharmaceuticals US INC $57.03 2023 Quviviq
Lundbeck LLC $48.98 2022
Sunovion Pharmaceuticals INC. $20.32 2022
Janssen Pharmaceuticals, INC $17.95 2023 Spravato

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Marquetta Williamson

$927.70

in general payments reported 2019-2025

Years
2021-2024
Top company
Alkermes, INC.

https://glasscript.com/doctor/5859175/marquetta-williamson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.